Orion Oyj Unsponsored ADR (OFK0)

Overview

Orion Oyj is a distinguished entity in the global healthcare sector, engrossed in the development, manufacturing, and marketing of pharmaceuticals for both human and veterinary use, in addition to active pharmaceutical ingredients (APIs). With its foundations laid in 1917, the company has established a strong presence not only in its native land of Finland and the broader Scandinavian region but also across Europe, North America, and several other international markets. Aside from its expertise in prescription medications and self-care products, Orion Oyj's operations also span across providing APIs for generic compounds, proprietary products, and extensive contract manufacturing services. Its strategic partnerships, such as with Propeller Health and Amneal Pharmaceuticals, Inc., further signify its collaborative approach towards innovation and expansion in the pharmaceutical domain.

Products and Services

• Prescription Drugs and Self-care Products

  Orion Oyj offers an extensive portfolio of prescription drugs including Nubeqa for prostate cancer; Precedex, Dexdor, and Precedex for human sedation; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer, and many others. The company also has a focus on treatments for Parkinson's disease through products like Stalevo, Entacapone, and Comtess/Comtan, in addition to Biosimilars for rheumatoid arthritis and inflammatory bowel diseases. Its contribution to heart failure treatment is marked by Simdax for acute decompensated heart failure and Fareston for breast cancer.

• Easyhaler Products for Respiratory Conditions

  The Easyhaler product line is targeted at patients suffering from asthma and chronic obstructive pulmonary disease, including Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler. These products are part of Orion Oyj's commitment to improving the quality of life for individuals with respiratory conditions.

• Veterinary Pharmaceuticals

  In the veterinary drug market, Orion Oyj has developed and marketed products like Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie. These products cater to the sedation, analgesia, and anesthesia needs of animals, alongside addressing specific conditions and improving animal health.

• Active Pharmaceutical Ingredients (APIs)

  Orion Oyj is instrumental in supplying APIs for a broad range of generic compounds and proprietary products. The company also extends its capabilities to offer contract manufacturing services, thereby providing comprehensive solutions from drug development to market.

• Partnerships and Collaborations

  The company has embraced strategic partnerships to enhance its product offerings and expand its market reach. Notably, its partnership with Propeller Health aims to integrate digital health tools with the Easyhaler® product portfolio, enhancing patient engagement and treatment adherence. Moreover, the research collaboration and license agreement with Amneal Pharmaceuticals, Inc., facilitate the commercialization of Amneal's generic products, exemplifying Orion Oyj's commitment to fostering innovation through partnerships.